AxoGen, Inc.

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

One-third of all the regenerative medicine advanced therapy (RMAT) designations granted by the US Food and Drug Administration’s Center for Biologics Evaluation and Research were awarded in fiscal yea

Clinical evidence is in, digitization for the sake of digitization is out this year, according to the experts who participated in a 31 January roundtable organized by Russo Partners. The panelists wer

For the third installment of our Scrip Asks…What Does 2023 Hold For Biopharma? series, we asked industry leaders and experts how the sector would be affected by the global headwinds of political ins